Castleview Partners LLC Grows Stake in Eli Lilly and Company (NYSE:LLY)

Castleview Partners LLC boosted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 45.1% in the 3rd quarter, Holdings Channel.com reports. The institutional investor owned 396 shares of the company’s stock after buying an additional 123 shares during the period. Castleview Partners LLC’s holdings in Eli Lilly and Company were worth $351,000 at the end of the most recent reporting period.

Other large investors have also recently modified their holdings of the company. First PREMIER Bank boosted its stake in Eli Lilly and Company by 4.3% in the first quarter. First PREMIER Bank now owns 556 shares of the company’s stock worth $432,000 after buying an additional 23 shares in the last quarter. CHICAGO TRUST Co NA grew its position in Eli Lilly and Company by 8.7% during the 1st quarter. CHICAGO TRUST Co NA now owns 6,223 shares of the company’s stock worth $4,841,000 after acquiring an additional 500 shares during the last quarter. Lloyd Advisory Services LLC. increased its stake in Eli Lilly and Company by 382.5% in the 1st quarter. Lloyd Advisory Services LLC. now owns 2,485 shares of the company’s stock worth $1,934,000 after purchasing an additional 1,970 shares during the period. Traynor Capital Management Inc. raised its holdings in Eli Lilly and Company by 38.5% during the 1st quarter. Traynor Capital Management Inc. now owns 30,833 shares of the company’s stock valued at $23,987,000 after buying an additional 8,563 shares during the last quarter. Finally, Range Financial Group LLC raised its holdings in Eli Lilly and Company by 1.5% during the 1st quarter. Range Financial Group LLC now owns 4,165 shares of the company’s stock valued at $3,240,000 after buying an additional 60 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

LLY traded down $9.69 during mid-day trading on Monday, reaching $908.28. 560,565 shares of the company traded hands, compared to its average volume of 2,972,419. The company’s fifty day moving average price is $921.21 and its 200-day moving average price is $858.60. The stock has a market capitalization of $863.23 billion, a P/E ratio of 134.33, a P/E/G ratio of 2.79 and a beta of 0.42. The company has a quick ratio of 0.87, a current ratio of 1.11 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 52-week low of $547.61 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating analysts’ consensus estimates of $2.64 by $1.28. The company had revenue of $11.30 billion for the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. On average, sell-side analysts expect that Eli Lilly and Company will post 16.49 EPS for the current year.

Analyst Ratings Changes

Several equities research analysts have weighed in on the company. Wells Fargo & Company increased their price objective on Eli Lilly and Company from $875.00 to $1,000.00 and gave the stock an “overweight” rating in a report on Friday, August 9th. Sanford C. Bernstein initiated coverage on Eli Lilly and Company in a research report on Thursday. They issued an “outperform” rating and a $1,100.00 target price for the company. Jefferies Financial Group upped their target price on shares of Eli Lilly and Company from $994.00 to $1,015.00 and gave the stock a “buy” rating in a research report on Monday, June 24th. Morgan Stanley reaffirmed an “overweight” rating and set a $1,106.00 price objective on shares of Eli Lilly and Company in a research report on Tuesday, August 27th. Finally, Citigroup assumed coverage on Eli Lilly and Company in a report on Friday, September 13th. They issued a “buy” rating and a $1,060.00 target price on the stock. Three analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,002.24.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.